Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jan 24, 2022; 13(1): 1-8
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.1
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.1
Update on the treatment of metastatic renal cell carcinoma
Rafael Antonio Medina López, Javier Mazuecos-Quirós, Carmen Belén Congregado-Ruíz, Department of Urology and Nephrology, Virgen del Rocío University Hospital, Biomedical Institute of Seville/CSIC/University of Seville, Sevilla 41013, Spain
Ines Rivero Belenchon, Department of Urology and Nephrology, Virgen del Rocío University Hospital, Seville 41005, Spain
Felipe Couñago, Radiation Oncology, Hospital Universitario Quirónsalud, Hospital La Luz, Universidad Europea de Madrid, Madrid 28223, Spain
Author contributions: Medina López RA, Rivero Belenchon I, Mazuecos-Quirós J, Congregado-Ruíz CB, and Couñago F contributed equally to the manuscript; all authors have read and approved the final manuscript.
Conflict-of-interest statement: Dr. Rivero Belenchon has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ines Rivero Belenchon, MD, Staff Physician, Department of Urology and Nephrology, Virgen del Rocío University Hospital, Manuel Siurot s/n, Seville 41005, Spain. ines.rivero.belenchon@gmail.com
Received: December 25, 2020
Peer-review started: December 25, 2020
First decision: September 29, 2021
Revised: October 5, 2021
Accepted: January 10, 2022
Article in press: January 10, 2022
Published online: January 24, 2022
Peer-review started: December 25, 2020
First decision: September 29, 2021
Revised: October 5, 2021
Accepted: January 10, 2022
Article in press: January 10, 2022
Published online: January 24, 2022
Core Tip
Core Tip: Kidney cancer therapeutics is a fast-changing field, and the outcome of metastatic renal cell carcinoma (mRCC) has thus improved considerably in recent years with the introduction of different combinations of immune checkpoint and vascular endothelial growth factors inhibitors. State-of-the-art systemic therapy regimens must be addressed to be in a position to offer patients the best options. The aim of this editorial is to provide an update and insight on future directions on mRCC management.